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Introduction 
Assisted reproductive technologies (ART) have
changed life for over 25 years for many reasons, main-
ly because of the first direct access to embryos in vitro
from human species and the possibility of conceiving
outside the body. After the first rush of enthusiasm as
regards to the latest scientific progresses, major ethical
and social issues arose about consequences of this new
method of conception. According to the general opin-
ion, the perception and valuing of human life and fami-
ly relationship have changed drastically. In the nineties
ART have developed rapidly due to many progresses in
knowledge and techniques as well as social pressure and
patient's demand. However these treatments were still
quite new for mankind. In order to protect individuals
against ethical abuses without inhibiting scientific pro-
gresses, a specific legal framework was necessary. 
But all the stakeholders including the public, the
patient lobby groups, the professionals, the members
of the parliament and finally the government were
soon convinced of the difficulties to comply with the
two following issues: the absolute need for protecting
individuals against the scientific and ethical abuses
and the respect for the innovations and the enthusiasm
of the researchers as well as their freedom.
An extensive and strong debate led to the French
law on bioethics in 1994 and reviewed in 2004. Revi-
sion was scheduled every five years in order to take
into account clinical experiences, latest development in
the scientific knowledge, new techniques and society's
evolving points of view. Currently France must review
this law. In order to vote a law which is convenient to a
majority, the government is organizing a large public
debate in 2009 before voting on the new text. 
Substantial differences exist from the open-up
"laissez faire" to the most restrictive one. Conse-
quently a large reproductive tourism has developed
particularly for egg donation or surrogacy. The med-
ical and ethical bad conditions in which ART patients
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First a general review will describe the existing
French legal provisions in ART in the context of a
large framework applying to healthcare. Then one of
the main tools of the framework, the French govern-
ment agency in charge of expertise and regulation in
ART and pre implantation genetic diagnosis (PGD),
will be presented. Some of the difficulties in applying
the French law in ART will be exposed. Finally
because of the development of a large cross border
reproductive care, harmonisation of the legal frame-
works must be discussed in Europe.
Existing French regulations
Legal provisions applying to ART belong to a large
and relevant framework including bioethics [1], pro-
tection of patients' rights [2] and biomedical research
[3]. The key principles consist of respect for human
life and human body integrity. Any kind of commercial
practices relating to the human body or element from
the human body is prohibited. Eugenic practices and
either reproductive or therapeutic cloning are also pro-
hibited. Failing to comply with the law can include
criminal penalties and revocation of authorization. 
The 2004 law on bioethics regulates different
domains such as genetic analyses, organ, tissue and
cells procurement, donation and transplant, prenatal
diagnosis, pre implantation genetic diagnosis (PGD),
research on embryo and embryonic cells and finally
ART. The ART specific provisions state that:
• payment to gamete donors for donation is prohibit-
ed. The donors can not be motivated by money. In
the same way, donors can not be under any kind of
pressure, from friends or family's members as well
as from the medical sector. 
• contracts for surrogacy are illegal
• anonymity is required between donors and recipients
In addition the access to ART is legally restricted to
certain civil status and conditions as follow:
ART are intended to help heterosexual couples with
medically diagnosed infertility to become parents.
However couples who present a high risk of transmis-
sion of a severe disease to the children or to one of the
partners can also have access to ART. In addition, the
man and the woman who form the couple must be
alive at the moment of the ART application. This
means that posthume use of cryopreserved sperm or
embryos in ART is forbidden, even if the deceased per-
son had consented before. They must be married or
able to prove that they have been living together for at
least two years.
Both must be of a natural reproductive age even if
it is very difficult to define limits particularly for men.
Increasing demands from women over 42 years old
who present a physiologic ovarian defect represent
new society's concerns.
Finally both must have given prior consent to ART
without any pressure. These consents are signed after
having received fair, clear and appropriate information
about the risks and consequences of the procedure. The
couples must participate in the decision making. The
consent signed by both members of the couple must be
repeated before each attempt. The medical team must
ensure that the information given has been fully under-
stood, that the persons have been able to ask all the
questions they wish and have had satisfactory answers.  
With respect to these general conditions, ART
should be accessible to everyone, regardless of finan-
cial and social conditions of life and whatever the
place of residence.
The definition of infertility as a disease is very spe-
cific to France. Indeed the law on bioethics defines
ART as medical care which are provided to infertile
couples. In France, health care are covered by the
national health insurance which is funded by national
workers participation.
Consequently, ART services are provided within
the organisational framework of the French national
healthcare system and fully covered. Conditions for a
free treatment are precisely defined in the national
health insurance code.
Good practices in ART [4] applying to the manage-
ment of patients and donors for all clinical and labora-
tory procedures complement the legal provisions. Reg-
ulating technical details, which are in constant evolu-
tion, are more flexible, easier and faster reviewed than
the law. Conformity to guidelines is obligatory for
both authorized establishments and licensed practi-
tioners. Failing to comply with these guidelines can
lead to a revocation of the authorization or license.
To conclude, the law stated some key principles
which are in agreement with current cultural values
and ethical considerations in France. However because
the revision of the law was scheduled every five years,
France must review its law. An extensive debate
including the public at large and patient associations
has started over the main issues at stake such as
anonymity of donation, payment to egg donors, surro-
gacy contracts and embryo research. A few people
would consider ART as a new mode of conception that
could be granted to lesbian couples, single women or
women up to 50 years old. So they lobby to lift the
legal barrier to access ART. It will be to the members
of the parliament to decide what the future law will be.
The French government agency in charge of
expertise and regulation in ART
Established by the law on bioethics in 2004, the
Agence de la biomédecine is a government agency
under the authority of the health ministry. It was creat-
ed to provide expertise and regulations in several main
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domains of human biology and medicine with com-
mon major medical and ethical issues. Its missions
focus on improving the quality and the safety of the
activities. It represents one of the main tools in the
French regulations applying to ART and PGD.
The agency draws its policy with
• an executive board of representatives from differ-
ent ministries, public bodies and experts, 
• a steering committee, which supervises the consis-
tency of the policy and the compliance with the eth-
ical principles. This committee is composed of
society's representatives, ethical and philosophy
specialists as well as parliament and legal represen-
tatives, patients representatives
• a medical and scientific committee composed of
experts, representative from professional associa-
tions from the different domains regulated by the
agency.
Finally the agency works closely with many specif-
ic groups of experts. Obviously the agency gives an
important role to civil society representatives and ART
practitioners.
First of all, the agency is the competent authority
delivering a technical expertise. It must be reactive,
ready to give a quick alert if necessary. Interacting
with society, it provides much valid information and
should contribute to reassure about such social or med-
ical concerns.
The main objectives can be summed up as follow:
1. Development of homogenous practices in the best
conditions of quality and safety everywhere in
France:
• contributing to guidelines 
• authorising practitioners 
• monitoring activities 
• training and information
2. Transparency:
• making evaluation of the activities and have them
available to the government, parliament, profes-
sionals and society. Complete information is avail-
able from the annual report available on the website
[5]
• conducting information campaigns with specific
public website and guides in ART, oocyte donation
and sperm donation [6] 
3. Ethics and fair access:
• ensuring that treatment is accessible to all 
So the agency has become the referent competent
authority for medical, scientific and ethical aspects in
ART. The following missions assigned to the agency
are detailed below:  
• licensing practitioners involved in ART, as well as
in genetics and PGD, taking into account their ini-
tial background and experiences 
• giving advices to the state health regional agencies
on the authorisation of the ART centres 
• evaluating activities and procuring a national
analysis in the annual report [7]
• organizing the collect of IVF data in a national reg-
ister in order to perform specific analyses
• organizing a long term follow up of the health of
the children born of ART and of the women who
performed ART or egg donation
• managing a vigilance system to centralize adverse
event declarations and give quick alerts if neces-
sary
• participating in development of new regulations
and guidelines; the agency worked with profession-
als to develop guidelines to harmonise practices  
• authorizing research on human embryos and
embryonic stem cells in vitro
• promoting of gamete donation
ART is organised and regulated in France and it is
well known at the European level. The agency attends
the European commission's meeting about all the
aspects of the transposition of the European directive
on tissues and cells [8] into the French law. It partici-
pates in many European projects including Eustite [9]
which applies to ART vigilance and inspections. The
agency is the second in Europe after the HFEA [10] in
UK. There are many exchanges with the Human Fer-
tilisation and Embryology Authority (HFEA) and
European Society of Human Reproduction and
Embryology (ESHRE) [11] particularly with the Euro-
pean Assisted Conception Consortium (EACC).
Main issues and need for harmonization
in Europe
Very few people contest the key principles stated by
the French law. But although the French law is not too
restrictive compared to some other legislations, a few
difficulties emerge with its enforcement. Just to quote
some of them: 
1. Because the law does not state anything about
research in ART, it is considered as forbidden. So
new techniques involving gametes and embryos are
prohibited. Whereas some new techniques are used
in other countries in a routine way improving the
success rate, these can not benefit French patients.
2. The attempt to define the human embryo's status
was unsuccessful. This leads to a certain inconsis-
tency authorizing induced abortion and forbidding
embryo research. 
Substantial differences in European legislations
exist. As a consequence a large reproductive tourism
exists particularly for egg donation or surrogacy. In
France, for many reasons egg donation is not devel-
oped enough to match the demand. This leads French
people to travel abroad to benefit from egg donation. 
In France ART activities are strictly regulated and
conformity to standards is mandatory for all the
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authorized ART centres and practitioners. Actually
such level of standards about quality and safety do not
apply to certain other countries including some Euro-
pean member states. This sometimes leads patients to
perform ART in bad conditions. Lack of donor's test-
ing before donation, false declaration of success rate,
or high risks of multiple pregnancies with severe
adverse outcomes constitute a few of the hazards for
patients receiving care abroad.
Moreover French provisions applying to gamete
donation anonymity and filiations rules are specific. The
consequences of gamete donation or surrogacy per-
formed abroad can be a disaster when back in France. 
In addition donor's recruitment is strictly restricted in
France in order to avoid gametes trafficking or exploita-
tion of human body parts. However some countries
have by-passed the difficulties to recruit donors by pay-
ing for donation. So oocyte donation provides earnings
particularly for poor Eastern European women who rep-
resent now the main sources of oocytes in rich coun-
tries. For these women, information regarding the risks
and consequences of the donation is often delivered in a
foreign language they can not understand. In those
countries where compensation is given in order to make
up for the hardness of the donation, donors can repeat
donation several times a year although egg donation and
surrogacy lead to high medical risks for life and health.
These women could have some difficulties to access
healthcare when they come back home with an adverse
event due to the donation. Particular attention should be
paid to these women.
The law should reassert the following key princi-
ple: the products of the human body should not be a
source of financial gain. Homogenization in legisla-
tions is necessary in Europe defining common ethical
principles in order to protect people against abuses.
The law should avoid technical details which are in
constant evolution. It must be completed by mandato-
ry good practices and professional guidelines which
are more flexible, easier and faster revised.  
In Europe, states are not isolated and Europe is cur-
rently being built. A new European legislation, making
patients free to travel for healthcare, is in preparation.
The 2004 European directive and its technical direc-
tives requiring the best quality and safety practices for
tissues and cells are fully transposed in most of the
member states now or in progress in the latest few
countries. The mother-directive encourages member
states to consider donation as a voluntary and unpaid
action founded on altruism and solidarity. 
Conclusion
ART activities have increased steadily for the last ten
years in many countries worldwide. In 2007 in France,
there were about 50,000 IUI cycles, 50,000 IVF or
ICSI cycles and 15,000 frozen embryo transfer cycles.
As a consequence, 2.5% babies born in 2007 were con-
ceived through ART in France. About 7% of the total
ART attempts are performed with a donation from a
third-party donor. These techniques could not be
ignored. Very few people question the efficiency of the
ART processes but afraid of the possible abuses they
are convinced that regulations are essential. 
ART, strictly regulated in France, is considered as a
medical treatment for infertile patients. All the legal
provisions converge to promote the best quality of the
practices and the protection of individuals against
medical abuses. However law is being reviewed and
many sensitive issues are arising. It is difficult to imag-
ine now what provisions will be modified, suppressed
or added.
The policies were differently shaped between coun-
tries even in Europe. The differences in legal frame-
work relating to ART have a huge impact on the allo-
cation of the techniques in the world. The technologies
used the social position of patients who have access to
ART and the recruitment of donors are widely hetero-
geneous and unfair.
As most of the countries such as France are cur-
rently reviewing their existing framework, policies
should be elaborated in order to make them homoge-
nous and relevant in Europe. Without ignoring each
context regarding cultural values, ethical considera-
tions, state secularism, public health issues and eco-
nomic means, key principles have to be strongly
asserted.
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